Table 1.
Effect of alogliptin treatment on the total and differential leucocytic counts in the BALF pellets of all experimental groups
| Groups | Total cells count × 105 | Neutrophils % | Eosinophils % | Lymphocytes % | Macrophages % |
|---|---|---|---|---|---|
| Control | 4.54 ± 0.11 | 2.83 ± 0.088 | 0.52 ± 0.01 | 13.23 ± 0.17 | 81 ± 1.6 |
| ALO | 4.6 ± 0.14 | 2.86 ± 0.09 | 0.51 ± 0.01 | 13.1 ± 0.25 | 80.5 ± 1.39 |
| CP | 12.8 ± 0.3*** | 47.55 ± 1.1*** | 5.2 ± 0.05*** | 35.33 ± 0.17*** | 12.11 ± 0.77*** |
| ALO + CP | 4.6 ± 0.12### | 9.8 ± 0.3***### | 1.13 ± 0.03***### | 9.6 ± 0.2***### | 71.62 ± 2.06**### |
Data are represented as the means ± standard error of mean (SEM); analyzed by One-way ANOVA followed by Tukey’s multiple comparisons test. A level of probability (P value) ≤ 0.05 was considered significant. * Significant versus control group; # significant versus CP-treated group. CP cyclophosphamide, ALO alogliptin, BALF bronchoalveolar lavage fluid